Skip to main content
Top
Published in: Archives of Virology 5/2010

01-05-2010 | Brief Report

Mutations in hepatitis C virus NS3 protease domain associated with resistance to specific protease inhibitors in antiviral therapy naïve patients

Authors: Allan Peres-da-Silva, Adilson José de Almeida, Elisabeth Lampe

Published in: Archives of Virology | Issue 5/2010

Login to get access

Abstract

The prevalence of naturally occurring mutations in hepatitis C virus associated with resistance to protease inhibitors in chronically infected patients has not been reported in Brazil. The NS3 serine protease domain was sequenced in 114 therapy-naïve patients infected with subtype 1a (n = 48), 1b (n = 53), or 3a (n = 13). A V36L mutation was observed in 5.6% patients infected with subtype 1b and in all isolates of the 3a subtype, and a T54S mutation was detected in 4.1% of isolates of subtype 1a. In conclusion, the presence of variants carrying mutations associated with resistance to protease inhibitors in therapy-naïve patients may be important for future therapeutic strategies.
Literature
2.
go back to reference Barbato G, Cicero DO, Nardi MC, Steinkühler C, Cortese R, De Francesco R et al (1999) The solution structure of the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein provides new insights into its activation and catalytic mechanism. J Mol Biol 289:371–384. doi:10.1006/jmbi.1999.2745 CrossRefPubMed Barbato G, Cicero DO, Nardi MC, Steinkühler C, Cortese R, De Francesco R et al (1999) The solution structure of the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein provides new insights into its activation and catalytic mechanism. J Mol Biol 289:371–384. doi:10.​1006/​jmbi.​1999.​2745 CrossRefPubMed
3.
go back to reference Bartels DJ, Zhou Y, Zhang EZ, Marcial M, Byrn RA, Pfeiffer T et al (2008) Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis 198:800–807. doi:10.1086/591141 CrossRefPubMed Bartels DJ, Zhou Y, Zhang EZ, Marcial M, Byrn RA, Pfeiffer T et al (2008) Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis 198:800–807. doi:10.​1086/​591141 CrossRefPubMed
5.
go back to reference Campiotto S, Pinho JR, Carrilho FJ, Da Silva LC, Souto FJ, Spinelli V et al (2006) Geographic distribution of hepatitis C virus genotypes in Brazil. Braz J Med Biol Res 39:41–49. doi:10.1590/S0100-879X2005000100007 Campiotto S, Pinho JR, Carrilho FJ, Da Silva LC, Souto FJ, Spinelli V et al (2006) Geographic distribution of hepatitis C virus genotypes in Brazil. Braz J Med Biol Res 39:41–49. doi:10.​1590/​S0100-879X200500010000​7
7.
go back to reference Colson P, Brouk N, Lembo F, Castellani P, Tamalet C, Gérolami R (2008) Natural presence of substitution R155K within hepatitis C virus NS3 protease from a treatment-naïve chronically infected patient. Hepatology 47:766–767. doi:10.1002/hep.22122 CrossRefPubMed Colson P, Brouk N, Lembo F, Castellani P, Tamalet C, Gérolami R (2008) Natural presence of substitution R155K within hepatitis C virus NS3 protease from a treatment-naïve chronically infected patient. Hepatology 47:766–767. doi:10.​1002/​hep.​22122 CrossRefPubMed
9.
go back to reference Fonseca JCF (1999) Epidemiologia da infecção pelo virus da hepatite C no Brasil. Relatório do Grupo de Estudo da Sociedade Brasileira de Hepatologia. GED Gastroenterol Endosc Dig 18(Supl 1):S3–8 Fonseca JCF (1999) Epidemiologia da infecção pelo virus da hepatite C no Brasil. Relatório do Grupo de Estudo da Sociedade Brasileira de Hepatologia. GED Gastroenterol Endosc Dig 18(Supl 1):S3–8
10.
go back to reference Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P et al (2004) Peginterferon alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140:346–355PubMed Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P et al (2004) Peginterferon alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140:346–355PubMed
11.
go back to reference Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK et al (2008) Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology 48:1769–1778. doi:10.1002/hep.22549 CrossRefPubMed Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK et al (2008) Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology 48:1769–1778. doi:10.​1002/​hep.​22549 CrossRefPubMed
12.
go back to reference Lin TI, Lenz O, Fanning G, Verbinnen T, Delouvroy F, Scholliers A et al (2009) In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother 53:1377–1385. doi:10.1128/AAC.01058-08 CrossRefPubMed Lin TI, Lenz O, Fanning G, Verbinnen T, Delouvroy F, Scholliers A et al (2009) In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother 53:1377–1385. doi:10.​1128/​AAC.​01058-08 CrossRefPubMed
14.
go back to reference López-Labrador FX, Moya A, Gonzàlez-Candelas F (2008) Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates. Antivir Ther 13:481–494PubMed López-Labrador FX, Moya A, Gonzàlez-Candelas F (2008) Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates. Antivir Ther 13:481–494PubMed
16.
go back to reference Rajagopalan R, Misialek S, Stevens S, Myszka D, Brandhuber B, Ballard J et al (2009) Inhibition and binding kinetics of the hepatitis C virus NS3 protease inhibitor ITMN-191 reveals tight binding and slow dissociative behavior. Biochemistry 48:2559–2568. doi:10.1021/bi900038p CrossRefPubMed Rajagopalan R, Misialek S, Stevens S, Myszka D, Brandhuber B, Ballard J et al (2009) Inhibition and binding kinetics of the hepatitis C virus NS3 protease inhibitor ITMN-191 reveals tight binding and slow dissociative behavior. Biochemistry 48:2559–2568. doi:10.​1021/​bi900038p CrossRefPubMed
17.
21.
go back to reference Tamura K, Dudley J, Nei M, Kumar S (2007) MEGA4: molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol Biol Evol 24:1596–1599. doi: 10.1093/molbev/msm092 Tamura K, Dudley J, Nei M, Kumar S (2007) MEGA4: molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol Biol Evol 24:1596–1599. doi: 10.​1093/​molbev/​msm092
24.
go back to reference Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG (1997) The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 25:4876–4882CrossRefPubMed Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG (1997) The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 25:4876–4882CrossRefPubMed
25.
go back to reference Welsch C, Domingues FS, Susser S, Antes I, Hartmann C, Mayr G, Schlicker A et al (2008) Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus. Genome Biol 9:R16. doi:10.1186/gb-2008-9-1-r16 CrossRefPubMed Welsch C, Domingues FS, Susser S, Antes I, Hartmann C, Mayr G, Schlicker A et al (2008) Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus. Genome Biol 9:R16. doi:10.​1186/​gb-2008-9-1-r16 CrossRefPubMed
26.
go back to reference Yan Y, Li Y, Munshi S, Sardana V, Cole JL, Sardana M et al (1998) Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 a resolution structure in a hexagonal crystal form. Protein Sci 7:837–847PubMedCrossRef Yan Y, Li Y, Munshi S, Sardana V, Cole JL, Sardana M et al (1998) Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 a resolution structure in a hexagonal crystal form. Protein Sci 7:837–847PubMedCrossRef
Metadata
Title
Mutations in hepatitis C virus NS3 protease domain associated with resistance to specific protease inhibitors in antiviral therapy naïve patients
Authors
Allan Peres-da-Silva
Adilson José de Almeida
Elisabeth Lampe
Publication date
01-05-2010
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 5/2010
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-010-0642-z

Other articles of this Issue 5/2010

Archives of Virology 5/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.